SCHEMBL29300085

SCHEMBL29300085

O=C(O)CC(CS)NCCNC(CS)CC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 3/20 0.42
ENPEP Q07075 3/20 0.42
SLC22A6 Q4U2R8 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
MME P08473 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
FOLH1 Q04609 1/20 0.32
PTGS1 P23219 1/20 0.32
SLC7A11 Q9UPY5 1/20 0.32
BMP1 P13497 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
ALOX15 P16050 1/20 0.31
NFKB1 P19838 1/20 0.31
PTGS2 P35354 1/20 0.31
THPO P40225 1/20 0.31
RECQL P46063 1/20 0.31
BLM P54132 1/20 0.31
GABRR1 P24046 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29299556 0.90 LMNA (0.43) ANPEPENPEPSLC22A6TDP1MME
SCHEMBL13078699 0.76
SCHEMBL3115669 0.73 FOLH1 (0.39) ANPEPENPEPSLC22A6TDP1SMN1; SMN2
SCHEMBL25554729 0.70 LMNA (0.45) SLC22A6TDP1MMESMN1; SMN2KDM4E
SCHEMBL10873512 0.70 ANPEP (0.37) ANPEPENPEPSLC22A6MME
SCHEMBL3840956 0.68 GABRR1 (0.43) SLC22A6TDP1NFKB1BLMGABRR1
SCHEMBL18645939 0.68 GPR84 (0.44) ALOX15
SCHEMBL8961847 0.67 LMNA (0.41) SLC22A6TDP1MAPTTHRBNFKB1
SCHEMBL3118980 0.66 FOLH1 (0.38) ANPEPENPEPSLC22A6FOLH1
SCHEMBL28968686 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R ANPEP 206/4885ENPEP 699/4885SLC22A6 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.